Preparation of Liposomal Amphotericin B (Ambisome) for Administration 

This video demonstrates the procedure for the preparation of liposomal amphotericin B (“L-AmB”), AmBisome® brand, for administration. L-AmB is an optimal product for the treatment of Cryptococcal Meningitis - a major opportunistic infection affecting people with Advanced HIV Disease (AHD). This video was developed in collaboration with the Infectious Disease Institute, Uganda, and made possible through the Unitaid-CHAI AHD Initiative.
AHD conditions are the leading causes of mortality in people living with HIV. With the growing global consensus on the need to address gaps in AHD diagnosis and treatment, the Unitaid-CHAI AHD Initiativewas launched to reduce morbidity and mortality by accelerating access to affordable, optimal products for the prevention, diagnosis and management of key opportunistic infections.
For further resources on AHD, including information about optimal AHD commodities, please refer to the Global AHD toolkit, which was developed by CHAI and other partners to support the rollout of the World Health Organization (WHO) recommended package of care for people with AHD